공시 • May 15
Newtopia Inc. announced that it has received CAD 1.6 million in funding Newtopia Inc. announced that it has received CAD 1.6 million in new senior secured debt financing om May 14, 2025. 공시 • Aug 28
Newtopia Inc., Annual General Meeting, Nov 08, 2024 Newtopia Inc., Annual General Meeting, Nov 08, 2024. 공시 • Aug 01
Newtopia Inc. to Report Q2, 2024 Results on Aug 08, 2024 Newtopia Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024 공시 • May 24
Newtopia Inc. to Report Q1, 2024 Results on May 23, 2024 Newtopia Inc. announced that they will report Q1, 2024 results After-Market on May 23, 2024 공시 • Mar 01
Newtopia Inc. announced that it has received CAD 0.7465 million in funding Newtopia Inc. a brokered private placement of 14,430,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 721,500; and a non-brokered private placement of 500,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 25,000; for aggregate gross proceeds of CAD 746,500 on February 29, 2024. The transaction included participation from Jeff Ruby, CEO of the company; Roger Poirier and Hugh G. McCauley for an aggregate of 1,110,000 units. Each unit is comprised of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one common share at an exercise price of CAD 0.10 per common share, subject to adjustments in certain events, until March 1, 2027. No fees or commissions are payable to the agent in connection with the non-brokered offering. A finder acting in connection with the non-brokered offering received a finder's fee in the aggregate total amount of CAD 1,250 and an aggregate of 25,000 finder's warrants exercisable for common shares on substantially the same terms as the broker warrants. In consideration for the services provided by the agent in connection with the brokered offering, the agent received a cash fee in the aggregate amount of CAD 38,675 and 721,000 non-transferable broker warrants. Each broker warrant is exercisable for one common share at the offering price, subject to adjustments in certain events, until March 1, 2026. All securities issued in connection with the offerings are subject to a hold period which will expire on June 30, 2024, the date that is four months and one day from the closing of the offerings. The offerings are subject to final acceptance of the TSX Venture Exchange. 공시 • Jan 29
Newtopia Launches "Glp-1 Sustain" Program to Affordably Preserve and Extend Valuable Health Benefits of Novel Weight Loss Drugs Newtopia Inc. announced GLP-1 Sustain, a companion program to specifically support and extend the dramatic clinical outcomes produced by glucagon-like-peptide-1 (GLP-1) receptor agonists and other related agonist drugs at a critical juncture in the patient journey - once a user first encounters a "weight loss plateau"i and even if users cease taking the medication entirely. In so doing, Newtopia'sGLP-1 Sustain brings to market a much-needed pathway to ensure that the many short-term health benefits of these medications may be long-lasting and that the significant costs to invest in them may in fact yield a positive ROI for payers, employers, value-based providers, and patients. Newtopia's habit change platform is already proven for its unrivaled ability to generate and maintain high levels of user-engagement for periods of two years and beyond. Newtopia leads the industry by consistently demonstrating 70% of its participants as actively engaged at 12 months, and over 60% engaged at 24 months. Through its unique engagement capabilities, Newtopia cultivates positive lifestyle habits among its participants focused on nutrition, exercise, and emotional well-being. According to published results of a randomized controlled clinical trial (RCT) on 2,835 individuals with increased waist circumference and at least one other metabolic risk factor, Newtopia's method for habit change produces significant beneficial change in several metabolic risk factors and an average weight loss of 10 pounds or 4.3% of the pre-program weight. Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years. Such durable clinical benefits lead to an annual cost savings of at least $1,464 per participant. Leveraging this very same habit change platform, Newtopia'sGLP-1 Sustain combines genetic testing for risk factors and key behaviors with individualized live coaching, curated content, and remote monitoring from smart devices to help any GLP-1 user identify, develop, and internalize constructive lifestyle habits necessary to sustain weight loss, health, and well-being over time – whether users remain on, or ultimately stop taking these medications. GLP-1 Sustain will also produce significant annual cost savings for Newtopia clients of ~$10,000+ per participant (i.e. the average annual cost of GLP-1 medications of ~$12,000 replaced post-plateau, or if users cease the medication, with the average annual value-based cost of Newtopia of ~$750). At less than 1/10th the cost of these drugs, GLP-1 Sustain offers a proven, scalable, and affordable pathway to preserve the weight loss and other health benefits produced by GLP-1 medications for millions of Americans. 